Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC). July 20, 2026 A ferroptosis-suppressive ...
Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...
Christopher Sweeney presents a Decipher® genomic classifier analysis of the ENZAMET trial, applying the 22-gene assay to evaluate whether genomic risk may help identify patients with metastatic ...
Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
Nectin-4 is a cell-adhesion molecule overexpressed in several malignancies and is a promising therapeutic target. Its expression profile and clinical relevance in prostate cancer (PCa) remain ...
Prostate cancer requiring radical prostatectomy surgery, invariably affects many aspects of men's lives. Whilst altered sexual function is well documented as a potential outcome of surgery, the impact ...
Hunner lesions (HL) are distinctive ulcerative bladder lesions characterized by a central scar and surrounding erythema. Traditionally, HL has been used as a clinical diagnostic tool for a subset of ...
The majority of bladder cancers are diagnosed as non-muscle invasive (NMIBC), with 90% over the age of 55. Although the incidence of several malignancies is increasing among younger adults in whom ...
SUMMARYUrinary tract infections (UTIs) are among the most common bacterial infections worldwide, with catheter-associated UTIs (CAUTIs) representing a major subset in healthcare settings. CAUTIs ...
Neeraj Agarwal discusses TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results